gdc-0623 (Genentech inc)
90
Structured Review
Genentech inc
gdc-0623
Gdc 0623, supplied by Genentech inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/gdc-0623/gdc+0623/pm37859720-182-9-7
Average 90 stars, based on 1 article reviews
Gdc 0623, supplied by Genentech inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/gdc-0623/gdc+0623/pm37859720-182-9-7
Average 90 stars, based on 1 article reviews
gdc-0623 - by Bioz Stars,
2026-09
90/100 stars
Images
Related Articles
Synthesized:Article Title: The ERK cascade inhibitors: Towards overcoming resistance. Article Snippet: The RAS–ERK pathway plays a major regulatory role in various cellular processes.. This pathway is hyperactivated and takes an active part in the malignant transformation of more than 85% of cancers.. The hyperactivation is mainly due to oncogenic activating mutations in the pathway’s components RAS, RAF and MEK, but also due to indirect mechanisms in cells transformed by other oncogenes. Article Title: MEK1/2 Inhibitors: Molecular Activity and Resistance Mechanisms Article Snippet: Interacts with Lys97 in the β3-strand and Ser212 in the activation loop. (PDB:3PP1) 3.2 nM for Article Title: Histone deacetylase inhibitors for the use in the treatment of drug resistant melanoma Article Snippet: Preferred examples of MEK inhibitors include Trametinib (GSK), Article Title: Combined MEK and ERK inhibition overcomes therapy-mediated pathway reactivation in RAS mutant tumors Article Snippet: Article Title: Targeting the ERK Signaling Pathway in Melanoma Article Snippet: Article Title: Thieno[3,2-d]pyrimidine derivative compound having inhibitory activity for protein kinase Article Snippet: Article Title: Current Development Status of MEK Inhibitors Article Snippet: GDC-0623 [ ] , MEK1/2 , 0.13 nM , Article Title: MEK inhibitors in cancer treatment: structural insights, regulation, recent advances and future perspectives. Article Snippet: MEK1/2 are critical components of the RAS–RAF–MEK–ERK or MAPK signalling pathway that regulates a variety of cellular functions including proliferation, survival, and differentiation.. In 1997, a lung cancer cell line was first found to have a MEK mutation (encoding MEK2P298L).. MEK is involved in various human cancers such as non-small cell lung cancer (NSCLC), spurious melanoma, and pancreatic, colorectal, basal, breast, and liver cancer. Suspension:Article Title: The ERK cascade inhibitors: Towards overcoming resistance. Article Snippet: The RAS–ERK pathway plays a major regulatory role in various cellular processes.. This pathway is hyperactivated and takes an active part in the malignant transformation of more than 85% of cancers.. The hyperactivation is mainly due to oncogenic activating mutations in the pathway’s components RAS, RAF and MEK, but also due to indirect mechanisms in cells transformed by other oncogenes. Article Title: MEK1/2 Inhibitors: Molecular Activity and Resistance Mechanisms Article Snippet: Interacts with Lys97 in the β3-strand and Ser212 in the activation loop. (PDB:3PP1) 3.2 nM for Article Title: Histone deacetylase inhibitors for the use in the treatment of drug resistant melanoma Article Snippet: Preferred examples of MEK inhibitors include Trametinib (GSK), Article Title: Combined MEK and ERK inhibition overcomes therapy-mediated pathway reactivation in RAS mutant tumors Article Snippet: Article Title: Targeting the ERK Signaling Pathway in Melanoma Article Snippet: Article Title: Thieno[3,2-d]pyrimidine derivative compound having inhibitory activity for protein kinase Article Snippet: Article Title: Current Development Status of MEK Inhibitors Article Snippet: GDC-0623 [ ] , MEK1/2 , 0.13 nM , Article Title: MEK inhibitors in cancer treatment: structural insights, regulation, recent advances and future perspectives. Article Snippet: MEK1/2 are critical components of the RAS–RAF–MEK–ERK or MAPK signalling pathway that regulates a variety of cellular functions including proliferation, survival, and differentiation.. In 1997, a lung cancer cell line was first found to have a MEK mutation (encoding MEK2P298L).. MEK is involved in various human cancers such as non-small cell lung cancer (NSCLC), spurious melanoma, and pancreatic, colorectal, basal, breast, and liver cancer. Activation Assay:Article Title: The ERK cascade inhibitors: Towards overcoming resistance. Article Snippet: The RAS–ERK pathway plays a major regulatory role in various cellular processes.. This pathway is hyperactivated and takes an active part in the malignant transformation of more than 85% of cancers.. The hyperactivation is mainly due to oncogenic activating mutations in the pathway’s components RAS, RAF and MEK, but also due to indirect mechanisms in cells transformed by other oncogenes. Article Title: MEK1/2 Inhibitors: Molecular Activity and Resistance Mechanisms Article Snippet: Interacts with Lys97 in the β3-strand and Ser212 in the activation loop. (PDB:3PP1) 3.2 nM for Article Title: Histone deacetylase inhibitors for the use in the treatment of drug resistant melanoma Article Snippet: Preferred examples of MEK inhibitors include Trametinib (GSK), Article Title: Combined MEK and ERK inhibition overcomes therapy-mediated pathway reactivation in RAS mutant tumors Article Snippet: Article Title: Targeting the ERK Signaling Pathway in Melanoma Article Snippet: Article Title: Thieno[3,2-d]pyrimidine derivative compound having inhibitory activity for protein kinase Article Snippet: Article Title: Current Development Status of MEK Inhibitors Article Snippet: GDC-0623 [ ] , MEK1/2 , 0.13 nM , Article Title: MEK inhibitors in cancer treatment: structural insights, regulation, recent advances and future perspectives. Article Snippet: MEK1/2 are critical components of the RAS–RAF–MEK–ERK or MAPK signalling pathway that regulates a variety of cellular functions including proliferation, survival, and differentiation.. In 1997, a lung cancer cell line was first found to have a MEK mutation (encoding MEK2P298L).. MEK is involved in various human cancers such as non-small cell lung cancer (NSCLC), spurious melanoma, and pancreatic, colorectal, basal, breast, and liver cancer. Inhibition:Article Title: The ERK cascade inhibitors: Towards overcoming resistance. Article Snippet: The RAS–ERK pathway plays a major regulatory role in various cellular processes.. This pathway is hyperactivated and takes an active part in the malignant transformation of more than 85% of cancers.. The hyperactivation is mainly due to oncogenic activating mutations in the pathway’s components RAS, RAF and MEK, but also due to indirect mechanisms in cells transformed by other oncogenes. Article Title: MEK1/2 Inhibitors: Molecular Activity and Resistance Mechanisms Article Snippet: Interacts with Lys97 in the β3-strand and Ser212 in the activation loop. (PDB:3PP1) 3.2 nM for Article Title: Histone deacetylase inhibitors for the use in the treatment of drug resistant melanoma Article Snippet: Preferred examples of MEK inhibitors include Trametinib (GSK), Article Title: Combined MEK and ERK inhibition overcomes therapy-mediated pathway reactivation in RAS mutant tumors Article Snippet: Article Title: Targeting the ERK Signaling Pathway in Melanoma Article Snippet: Article Title: Thieno[3,2-d]pyrimidine derivative compound having inhibitory activity for protein kinase Article Snippet: Article Title: Current Development Status of MEK Inhibitors Article Snippet: GDC-0623 [ ] , MEK1/2 , 0.13 nM , Article Title: MEK inhibitors in cancer treatment: structural insights, regulation, recent advances and future perspectives. Article Snippet: MEK1/2 are critical components of the RAS–RAF–MEK–ERK or MAPK signalling pathway that regulates a variety of cellular functions including proliferation, survival, and differentiation.. In 1997, a lung cancer cell line was first found to have a MEK mutation (encoding MEK2P298L).. MEK is involved in various human cancers such as non-small cell lung cancer (NSCLC), spurious melanoma, and pancreatic, colorectal, basal, breast, and liver cancer. Activity Assay:Article Title: The ERK cascade inhibitors: Towards overcoming resistance. Article Snippet: The RAS–ERK pathway plays a major regulatory role in various cellular processes.. This pathway is hyperactivated and takes an active part in the malignant transformation of more than 85% of cancers.. The hyperactivation is mainly due to oncogenic activating mutations in the pathway’s components RAS, RAF and MEK, but also due to indirect mechanisms in cells transformed by other oncogenes. Article Title: MEK1/2 Inhibitors: Molecular Activity and Resistance Mechanisms Article Snippet: Interacts with Lys97 in the β3-strand and Ser212 in the activation loop. (PDB:3PP1) 3.2 nM for Article Title: Histone deacetylase inhibitors for the use in the treatment of drug resistant melanoma Article Snippet: Preferred examples of MEK inhibitors include Trametinib (GSK), Article Title: Combined MEK and ERK inhibition overcomes therapy-mediated pathway reactivation in RAS mutant tumors Article Snippet: Article Title: Targeting the ERK Signaling Pathway in Melanoma Article Snippet: Article Title: Thieno[3,2-d]pyrimidine derivative compound having inhibitory activity for protein kinase Article Snippet: Article Title: Current Development Status of MEK Inhibitors Article Snippet: GDC-0623 [ ] , MEK1/2 , 0.13 nM , Article Title: MEK inhibitors in cancer treatment: structural insights, regulation, recent advances and future perspectives. Article Snippet: MEK1/2 are critical components of the RAS–RAF–MEK–ERK or MAPK signalling pathway that regulates a variety of cellular functions including proliferation, survival, and differentiation.. In 1997, a lung cancer cell line was first found to have a MEK mutation (encoding MEK2P298L).. MEK is involved in various human cancers such as non-small cell lung cancer (NSCLC), spurious melanoma, and pancreatic, colorectal, basal, breast, and liver cancer. Phospho-proteomics:Article Title: The ERK cascade inhibitors: Towards overcoming resistance. Article Snippet: The RAS–ERK pathway plays a major regulatory role in various cellular processes.. This pathway is hyperactivated and takes an active part in the malignant transformation of more than 85% of cancers.. The hyperactivation is mainly due to oncogenic activating mutations in the pathway’s components RAS, RAF and MEK, but also due to indirect mechanisms in cells transformed by other oncogenes. Article Title: MEK1/2 Inhibitors: Molecular Activity and Resistance Mechanisms Article Snippet: Interacts with Lys97 in the β3-strand and Ser212 in the activation loop. (PDB:3PP1) 3.2 nM for Article Title: Histone deacetylase inhibitors for the use in the treatment of drug resistant melanoma Article Snippet: Preferred examples of MEK inhibitors include Trametinib (GSK), Article Title: Combined MEK and ERK inhibition overcomes therapy-mediated pathway reactivation in RAS mutant tumors Article Snippet: Article Title: Targeting the ERK Signaling Pathway in Melanoma Article Snippet: Article Title: Thieno[3,2-d]pyrimidine derivative compound having inhibitory activity for protein kinase Article Snippet: Article Title: Current Development Status of MEK Inhibitors Article Snippet: GDC-0623 [ ] , MEK1/2 , 0.13 nM , Article Title: MEK inhibitors in cancer treatment: structural insights, regulation, recent advances and future perspectives. Article Snippet: MEK1/2 are critical components of the RAS–RAF–MEK–ERK or MAPK signalling pathway that regulates a variety of cellular functions including proliferation, survival, and differentiation.. In 1997, a lung cancer cell line was first found to have a MEK mutation (encoding MEK2P298L).. MEK is involved in various human cancers such as non-small cell lung cancer (NSCLC), spurious melanoma, and pancreatic, colorectal, basal, breast, and liver cancer. Mutagenesis:Article Title: The ERK cascade inhibitors: Towards overcoming resistance. Article Snippet: The RAS–ERK pathway plays a major regulatory role in various cellular processes.. This pathway is hyperactivated and takes an active part in the malignant transformation of more than 85% of cancers.. The hyperactivation is mainly due to oncogenic activating mutations in the pathway’s components RAS, RAF and MEK, but also due to indirect mechanisms in cells transformed by other oncogenes. Article Title: MEK1/2 Inhibitors: Molecular Activity and Resistance Mechanisms Article Snippet: Interacts with Lys97 in the β3-strand and Ser212 in the activation loop. (PDB:3PP1) 3.2 nM for Article Title: Histone deacetylase inhibitors for the use in the treatment of drug resistant melanoma Article Snippet: Preferred examples of MEK inhibitors include Trametinib (GSK), Article Title: Combined MEK and ERK inhibition overcomes therapy-mediated pathway reactivation in RAS mutant tumors Article Snippet: Article Title: Targeting the ERK Signaling Pathway in Melanoma Article Snippet: Article Title: Thieno[3,2-d]pyrimidine derivative compound having inhibitory activity for protein kinase Article Snippet: Article Title: Current Development Status of MEK Inhibitors Article Snippet: GDC-0623 [ ] , MEK1/2 , 0.13 nM , Article Title: MEK inhibitors in cancer treatment: structural insights, regulation, recent advances and future perspectives. Article Snippet: MEK1/2 are critical components of the RAS–RAF–MEK–ERK or MAPK signalling pathway that regulates a variety of cellular functions including proliferation, survival, and differentiation.. In 1997, a lung cancer cell line was first found to have a MEK mutation (encoding MEK2P298L).. MEK is involved in various human cancers such as non-small cell lung cancer (NSCLC), spurious melanoma, and pancreatic, colorectal, basal, breast, and liver cancer. Sequencing:Article Title: The ERK cascade inhibitors: Towards overcoming resistance. Article Snippet: The RAS–ERK pathway plays a major regulatory role in various cellular processes.. This pathway is hyperactivated and takes an active part in the malignant transformation of more than 85% of cancers.. The hyperactivation is mainly due to oncogenic activating mutations in the pathway’s components RAS, RAF and MEK, but also due to indirect mechanisms in cells transformed by other oncogenes. Article Title: MEK1/2 Inhibitors: Molecular Activity and Resistance Mechanisms Article Snippet: Interacts with Lys97 in the β3-strand and Ser212 in the activation loop. (PDB:3PP1) 3.2 nM for Article Title: Histone deacetylase inhibitors for the use in the treatment of drug resistant melanoma Article Snippet: Preferred examples of MEK inhibitors include Trametinib (GSK), Article Title: Combined MEK and ERK inhibition overcomes therapy-mediated pathway reactivation in RAS mutant tumors Article Snippet: Article Title: Targeting the ERK Signaling Pathway in Melanoma Article Snippet: Article Title: Thieno[3,2-d]pyrimidine derivative compound having inhibitory activity for protein kinase Article Snippet: Article Title: Current Development Status of MEK Inhibitors Article Snippet: GDC-0623 [ ] , MEK1/2 , 0.13 nM , Article Title: MEK inhibitors in cancer treatment: structural insights, regulation, recent advances and future perspectives. Article Snippet: MEK1/2 are critical components of the RAS–RAF–MEK–ERK or MAPK signalling pathway that regulates a variety of cellular functions including proliferation, survival, and differentiation.. In 1997, a lung cancer cell line was first found to have a MEK mutation (encoding MEK2P298L).. MEK is involved in various human cancers such as non-small cell lung cancer (NSCLC), spurious melanoma, and pancreatic, colorectal, basal, breast, and liver cancer. Produced:Article Title: The ERK cascade inhibitors: Towards overcoming resistance. Article Snippet: The RAS–ERK pathway plays a major regulatory role in various cellular processes.. This pathway is hyperactivated and takes an active part in the malignant transformation of more than 85% of cancers.. The hyperactivation is mainly due to oncogenic activating mutations in the pathway’s components RAS, RAF and MEK, but also due to indirect mechanisms in cells transformed by other oncogenes. Article Title: MEK1/2 Inhibitors: Molecular Activity and Resistance Mechanisms Article Snippet: Interacts with Lys97 in the β3-strand and Ser212 in the activation loop. (PDB:3PP1) 3.2 nM for Article Title: Histone deacetylase inhibitors for the use in the treatment of drug resistant melanoma Article Snippet: Preferred examples of MEK inhibitors include Trametinib (GSK), Article Title: Combined MEK and ERK inhibition overcomes therapy-mediated pathway reactivation in RAS mutant tumors Article Snippet: Article Title: Targeting the ERK Signaling Pathway in Melanoma Article Snippet: Article Title: Thieno[3,2-d]pyrimidine derivative compound having inhibitory activity for protein kinase Article Snippet: Article Title: Current Development Status of MEK Inhibitors Article Snippet: GDC-0623 [ ] , MEK1/2 , 0.13 nM , Article Title: MEK inhibitors in cancer treatment: structural insights, regulation, recent advances and future perspectives. Article Snippet: MEK1/2 are critical components of the RAS–RAF–MEK–ERK or MAPK signalling pathway that regulates a variety of cellular functions including proliferation, survival, and differentiation.. In 1997, a lung cancer cell line was first found to have a MEK mutation (encoding MEK2P298L).. MEK is involved in various human cancers such as non-small cell lung cancer (NSCLC), spurious melanoma, and pancreatic, colorectal, basal, breast, and liver cancer. Software:Article Title: The ERK cascade inhibitors: Towards overcoming resistance. Article Snippet: The RAS–ERK pathway plays a major regulatory role in various cellular processes.. This pathway is hyperactivated and takes an active part in the malignant transformation of more than 85% of cancers.. The hyperactivation is mainly due to oncogenic activating mutations in the pathway’s components RAS, RAF and MEK, but also due to indirect mechanisms in cells transformed by other oncogenes. Article Title: MEK1/2 Inhibitors: Molecular Activity and Resistance Mechanisms Article Snippet: Interacts with Lys97 in the β3-strand and Ser212 in the activation loop. (PDB:3PP1) 3.2 nM for Article Title: Histone deacetylase inhibitors for the use in the treatment of drug resistant melanoma Article Snippet: Preferred examples of MEK inhibitors include Trametinib (GSK), Article Title: Combined MEK and ERK inhibition overcomes therapy-mediated pathway reactivation in RAS mutant tumors Article Snippet: Article Title: Targeting the ERK Signaling Pathway in Melanoma Article Snippet: Article Title: Thieno[3,2-d]pyrimidine derivative compound having inhibitory activity for protein kinase Article Snippet: Article Title: Current Development Status of MEK Inhibitors Article Snippet: GDC-0623 [ ] , MEK1/2 , 0.13 nM , Article Title: MEK inhibitors in cancer treatment: structural insights, regulation, recent advances and future perspectives. Article Snippet: MEK1/2 are critical components of the RAS–RAF–MEK–ERK or MAPK signalling pathway that regulates a variety of cellular functions including proliferation, survival, and differentiation.. In 1997, a lung cancer cell line was first found to have a MEK mutation (encoding MEK2P298L).. MEK is involved in various human cancers such as non-small cell lung cancer (NSCLC), spurious melanoma, and pancreatic, colorectal, basal, breast, and liver cancer. Binding Assay:Article Title: The ERK cascade inhibitors: Towards overcoming resistance. Article Snippet: The RAS–ERK pathway plays a major regulatory role in various cellular processes.. This pathway is hyperactivated and takes an active part in the malignant transformation of more than 85% of cancers.. The hyperactivation is mainly due to oncogenic activating mutations in the pathway’s components RAS, RAF and MEK, but also due to indirect mechanisms in cells transformed by other oncogenes. Article Title: MEK1/2 Inhibitors: Molecular Activity and Resistance Mechanisms Article Snippet: Interacts with Lys97 in the β3-strand and Ser212 in the activation loop. (PDB:3PP1) 3.2 nM for Article Title: Histone deacetylase inhibitors for the use in the treatment of drug resistant melanoma Article Snippet: Preferred examples of MEK inhibitors include Trametinib (GSK), Article Title: Combined MEK and ERK inhibition overcomes therapy-mediated pathway reactivation in RAS mutant tumors Article Snippet: Article Title: Targeting the ERK Signaling Pathway in Melanoma Article Snippet: Article Title: Thieno[3,2-d]pyrimidine derivative compound having inhibitory activity for protein kinase Article Snippet: Article Title: Current Development Status of MEK Inhibitors Article Snippet: GDC-0623 [ ] , MEK1/2 , 0.13 nM , Article Title: MEK inhibitors in cancer treatment: structural insights, regulation, recent advances and future perspectives. Article Snippet: MEK1/2 are critical components of the RAS–RAF–MEK–ERK or MAPK signalling pathway that regulates a variety of cellular functions including proliferation, survival, and differentiation.. In 1997, a lung cancer cell line was first found to have a MEK mutation (encoding MEK2P298L).. MEK is involved in various human cancers such as non-small cell lung cancer (NSCLC), spurious melanoma, and pancreatic, colorectal, basal, breast, and liver cancer. Clinical Proteomics:Article Title: The ERK cascade inhibitors: Towards overcoming resistance. Article Snippet: The RAS–ERK pathway plays a major regulatory role in various cellular processes.. This pathway is hyperactivated and takes an active part in the malignant transformation of more than 85% of cancers.. The hyperactivation is mainly due to oncogenic activating mutations in the pathway’s components RAS, RAF and MEK, but also due to indirect mechanisms in cells transformed by other oncogenes. Article Title: MEK1/2 Inhibitors: Molecular Activity and Resistance Mechanisms Article Snippet: Interacts with Lys97 in the β3-strand and Ser212 in the activation loop. (PDB:3PP1) 3.2 nM for Article Title: Histone deacetylase inhibitors for the use in the treatment of drug resistant melanoma Article Snippet: Preferred examples of MEK inhibitors include Trametinib (GSK), Article Title: Combined MEK and ERK inhibition overcomes therapy-mediated pathway reactivation in RAS mutant tumors Article Snippet: Article Title: Targeting the ERK Signaling Pathway in Melanoma Article Snippet: Article Title: Thieno[3,2-d]pyrimidine derivative compound having inhibitory activity for protein kinase Article Snippet: Article Title: Current Development Status of MEK Inhibitors Article Snippet: GDC-0623 [ ] , MEK1/2 , 0.13 nM , Article Title: MEK inhibitors in cancer treatment: structural insights, regulation, recent advances and future perspectives. Article Snippet: MEK1/2 are critical components of the RAS–RAF–MEK–ERK or MAPK signalling pathway that regulates a variety of cellular functions including proliferation, survival, and differentiation.. In 1997, a lung cancer cell line was first found to have a MEK mutation (encoding MEK2P298L).. MEK is involved in various human cancers such as non-small cell lung cancer (NSCLC), spurious melanoma, and pancreatic, colorectal, basal, breast, and liver cancer. |
